Strategic partnerships Fry Laboratories has a history of collaborating with Beckman Coulter and BioID Genomics on next generation sequencing and rapid diagnostics for SARS-CoV-2, indicating a proven openness to co-development and integration with major instrument and genomics players. This suggests sales opportunities in collaborative automation, integration services, and co-marketed solutions with leading equipment and genomics vendors.

NGS leadership The company has actively developed and launched NGS assays for viral detection, including SARS-CoV-2, supported by multiple Beckman Coulter collaborations. This positions Fry Labs as a potential partner for expanding next-generation sequencing workflows, library preparation automation, and high-throughput infectious disease diagnostics opportunities.

Clinical diagnostics niche Operating as an independent clinical diagnostic and research lab focused on chronic diseases and inflammatory conditions with capabilities in microscopy, co-infection serology, biofilm detection, and species-level sequencing. This creates potential for contract research, assay validation services, and targeted diagnostic collaborations with specialty clinics and disease-focused biotechs.

Quality and reach Participation in CAP and API quality control programs and provision of worldwide testing services indicate a strong quality framework and scalable capability. This can be leveraged to offer quality assurance, proficiency testing partnerships, and international lab services for organizations seeking compliant, global diagnostic support.

Growth potential Moderate revenue range (one to several million dollars) combined with strategic tech stack and ongoing collaborations suggests opportunities to scale via service line expansion, paid pilot programs, and channel partnerships with larger reference labs or CROs seeking niche infectious disease and inflammatory disease diagnostics expertise.